In part 4 of this Exclusive Interview, Jon Odorico talks with Diabetes in Control during the ADA 2018 convention in Orlando about how research of stem cell derived beta cells has moved beyond academic labs to researchers in other arenas in the study of stem cell technology.
Jon Odorico MD is Director of the Pancreas and Islet Cell Transplantation Programs and Professor in the Department of Surgery, Division of Organ Transplantation at the University of Wisconsin-Madison School of Medicine and Public Health.
Transcript of this video segment:
Who is Involved in Research of Stem Cell-Derived Beta Cells?
Odorico: The work in this arena of stem cell-derived beta cells has now moved beyond academics. There are more and more academic labs interested and involved in doing good research in this area. But of late, several biotech companies have spun out of work in this area. They include Semma Therapeutics, Novo Nordisk, EvoTech Santa Fe, Regenerative Medical Solutions, and several others, including stem cell encapsulation technologies that are being promoted by Sigilon as well as Beta-O2.